Skip to main content

Advertisement

Table 1 Cell cycle progression of MSTO-211H cells treated with ZOL and/or Ad-delE1B55

From: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

Time (hrs) Treatment Cell cycle distribution (% ± SE)
Sub-G1 G1 S G2/M >4 N
24 (−) 2.04 ± 0.04 58.80 ± 0.20 18.17 ± 0.24 20.67 ± 0.31 0.81 ± 0.06
  Ad-LacZ 2.90 ± 0.16 57.30 ± 0.19 17.59 ± 0.22 20.97 ± 0.26 1.83 ± 0.04
  Ad-delE1B55 2.61 ± 0.16 55.29 ± 0.07 20.41 ± 0.11 20.08 ± 0.27 2.22 ± 0.11
  ZOL 2.47 ± 0.05 57.47 ± 0.10 18.34 ± 0.27 20.70 ± 0.22 1.62 ± 0.09
  ZOL + Ad-LacZ 3.58 ± 0.17 55.98 ± 0.16 17.94 ± 0.17 20.84 ± 0.10 2.22 ± 0.08
  ZOL + Ad-delE1B55 3.72 ± 0.05 53.99 ± 0.11 20.53 ± 0.23 19.42 ± 0.35 3.00 ± 0.09
48 (−) 1.73 ± 0.07 76.54 ± 0.12 8.20 ± 0.03 12.59 ± 0.08 1.18 ± 0.04
  Ad-LacZ 1.37 ± 0.08 75.90 ± 0.38 8.60 ± 0.16 12.55 ± 0.33 1.82 ± 0.03
  Ad-delE1B55 12.25 ± 0.04 51.87 ± 0.21 12.47 ± 0.13 21.56 ± 0.19 2.32 ± 0.03
  ZOL 3.82 ± 0.08 76.77 ± 0.43 6.70 ± 0.09 11.31 ± 0.33 1.60 ± 0.01
  ZOL + Ad-LacZ 2.81 ± 0.11 76.08 ± 0.33 7.47 ± 0.12 11.95 ± 0.13 1.96 ± 0.06
  ZOL + Ad-delE1B55 19.69 ± 0.18a 47.47 ± 0.19a 15.42 ± 0.44a 15.23 ± 0.35 2.69 ± 0.16
72 (−) 0.96 ± 0.02 87.55 ± 0.01 3.77 ± 0.13 7.26 ± 0.19 0.59 ± 0.05
  Ad-LacZ 1.46 ± 0.10 87.58 ± 0.30 2.75 ± 0.05 7.79 ± 0.14 0.51 ± 0.03
  Ad-delE1B55 22.52 ± 0.07 43.47 ± 0.18 11.57 ± 0.14 12.89 ± 0.23 10.14 ± 0.23
  ZOL 11.19 ± 0.08 76.77 ± 0.28 3.45 ± 0.08 7.93 ± 0.20 0.81 ± 0.12
  ZOL + Ad-LacZ 6.44 ± 0.03 80.27 ± 0.15 3.04 ± 0.04 9.66 ± 0.13 0.78 ± 0.04
  ZOL + Ad-delE1B55 35.52 ± 0.05a 24.06 ± 0.30a 13.89 ± 0.13b 11.83 ± 0.21 15.41 ± 0.19
96 (−) 1.03 ± 0.07 87.25 ± 0.01 4.43 ± 0.03 6.93 ± 0.06 0.50 ± 0.03
  Ad-LacZ 1.16 ± 0.06 87.36 ± 0.28 3.34 ± 0.17 7.65 ± 0.11 0.68 ± 0.04
  Ad-delE1B55 12.14 ± 0.27 53.92 ± 0.29 11.93 ± 0.06 13.21 ± 0.27 9.32 ± 0.31
  ZOL 9.32 ± 0.11 80.72 ± 0.21 3.98 ± 0.06 5.73 ± 0.07 0.40 ± 0.07
  ZOL + Ad-LacZ 8.93 ± 0.17 78.40 ± 0.17 4.22 ± 0.14 7.92 ± 0.13 0.79 ± 0.04
  ZOL+ Ad-delE1B55 40.75 ± 0.08a 21.50 ± 0.21a 14.26 ± 0.11b 10.58 ± 0.12 13.59 ± 0.18b
  1. Cells were treated with ZOL (10 μM) and/or either Ad-delE1B55 or Ad-LacZ (4.5 × 103 vp/cell) and cultured for 24–96 h. Cell cycle profiles were analyzed with flow cytometry. Averages with SEs are shown (n = 3)
  2. a p < 0.01, b p < 0.05; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells